Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
14 resultados
Anti-inflammatory Status in DM2 Treated Patients
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate leading to formation of
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The objective of this study is to compare the risk of major adverse cardiac events (MACE) associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in comparison with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes.
A common-protocol
Role of Endothelial Biomarkers in Patients With Coronary Artery Disease
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
1. We are aiming to establish a marker for chronic reactivation and pathophysiology of CMV infection in patients with coronary artery disease.
2. We will be able to answer whether there is a link between the seropositive CMV, telomere length, and CAD.
3. We will correlate the seropositive CMV with
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Type 2 diabetes mellitus remains a major risk factor for cardiovascular disease with an estimated 425 million adults worldwide having diabetes in 2017, with type 2 diabetes mellitus accounting for about 90% of the cases. Recent evidence indicates that certain glucose-lowering therapies are
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death.A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients.Dipeptidyl
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Background:
Patients with symptoms and signs of ischemia are referred to coronary angiography (CAG) or CT angiography (CT-CAG). A significant proportion of these patients and especially women appear to have no obstructive coronary stenosis. Patients with angina-like symptoms and no macrovascular
Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
APPROACH:
Overview of Study Design: This is a double-masked, randomized, placebo-controlled pilot study of treatment sitagliptin (100mg/day) to suppress monocyte/macrophage activation in obese non-diabetic participants. 16 abdominally obese18-40 year-old largely minorities will be randomized 3:1 to
Saxagliptin and Cardiac Structure and Function
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The cardiovascular safety and potential cardioprotective effects of diabetes drugs have been the focus of recent research. Currently, the Food and Drug Administration (FDA) requires all new anti-diabetic drugs to demonstrate no important increase in cardiovascular adverse events before
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Background:
Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of four recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1c. In the approval process,
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
1. Background Complications of diabetes could cause death from stroke and myocardial infarction, and it is the chronic disease that leads to foot amputation, blindness and renal failure. According to the data of Statistics Korea, the prevalence rate of diabetes for people over 30 years old
DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Randomized clinical trial,double-blinded,placebo-controlled, in a single center, to assess the influence of DPP4-i on platelet aggregability in type 2 diabetic patients with acute myocardial infarction in use of dual anti platelet therapy (DAPT) .
Others exploratory analysis include:glycemic control
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
T2DM in the young
T2DM has traditionally been associated with older age, with type 1 diabetes (T1DM) being the dominant form in younger populations. This traditional profile has dramatically altered over the last couple of decades; the sharp rise in levels of obesity and sedentary lifestyles
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by hyperglycemia that result from pancreatic islet dysfunction. Presently available oral antihypoglycemic drug improves glycemic control over the short term, none has been shown to stop the progressive decline in beta
The Vascular Effects of Vildagliptin in Insulin Resistant Individuals
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
After food intake, insulin secretion depends not only on the degree of glycemia, but also on the secretion and insulinotropic effect of the gut hormones, gastric inhibitory polypeptide (or glucose-dependent insulinotropic polypeptide; GIP) and glucagon-like polypeptide 1 (GLP-1), known as incretins.
O mais completo banco de dados de ervas medicinais apoiado pela ciência
- Funciona em 55 idiomas
- Curas herbais apoiadas pela ciência
- Reconhecimento de ervas por imagem
- Mapa GPS interativo - marcar ervas no local (em breve)
- Leia publicações científicas relacionadas à sua pesquisa
- Pesquise ervas medicinais por seus efeitos
- Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes
Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas
